<DOC>
	<DOCNO>NCT02924376</DOCNO>
	<brief_summary>The purpose study evaluate efficacy INCB054828 subject advanced/metastatic surgically unresectable cholangiocarcinoma FGFR2 translocation fail least 1 previous treatment .</brief_summary>
	<brief_title>Efficacy Safety INCB054828 Subjects With Advanced/Metastatic Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Histologically cytologically confirm cholangiocarcinoma . Radiographically measurable evaluable disease per RECIST v1.1 . Tumor assessment FGF/FGFR gene alteration status complete central laboratory . Documented disease progression least 1 line prior systemic therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Life expectancy â‰¥ 12 week . Prior receipt selective FGFR inhibitor . History and/or current evidence ectopic mineralization/calcification , include limited soft tissue , kidney , intestine , myocardium , lung , except calcify lymph node asymptomatic arterial cartilage/tendon calcification . Current evidence corneal disorder/keratopathy , include limited bullous/band keratopathy , corneal abrasion , inflammation/ulceration , keratoconjunctivitis , etc , confirm ophthalmologic examination . Use potent CYP3A4 inhibitor inducer within 14 day 5 halflives , whichever short , first dose study drug . Topical ketoconazole allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>fibroblast growth factor ( FGF )</keyword>
	<keyword>fibroblast growth factor receptor ( FGFR )</keyword>
	<keyword>FGF/FGFR alteration</keyword>
</DOC>